More on Spectrum Pharmaceuticals ([SPPI]] +1%) Q4: net profit edges up to $8.6M as revenues essentially remain flat for the third quarter in a row. Top line hurt by falling sales of Fusilev (colon), which drop 14% Q/Q to $44.6M, possibly due to resupply of cheaper leucovorin generic. Forecasts increase in 2013 revenue and operating income but doesn't provide specific guidance.
More on Spectrum Pharmaceuticals ([SPPI]] +1%) Q4: net profit edges up to $8.6M as revenues...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs